In a move “signaling the growing momentum for using clinical data to transform healthcare,” Deloitte said it is looking to expand in health management and accountable care analytics.
Recombinant is a provider of enterprise data integration, population health analytics and performance management in the government health, medical research and life sciences markets.
Andrew Vaz, chief innovation officer at Deloitte, said the company was considering a number of healthcare companies for about three years before deciding on Recombinant.
Vaz added that the acquisition will combine Recombinant’s products and software with Deloitte’s consulting capabilities and is expected “to bring to bear some strong combined capabilities in a hyper business model.”
Nitin Mittal, senior manager at Deloitte, said Recombinant’s focus on the secondary usage of data is key. “The intent is to see if there are secondary usages for drugs or repurposed drugs beyond the primary area it’s targeted for,” Mittal said.
Recombinant works with several teaching hospitals at various universities to help “build a cohesive picture across genotypic data.”
Recombinant’s business will reside within Deloitte Consulting, under the title “Recombinant by Deloitte.”